Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212281 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL213091 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL214805 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL213092 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL213509 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL212282 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL213508 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3GFER | |
| SCHEMBL213817 | 0.97 | — | — | |
| SCHEMBL213818 | 0.97 | — | — | |
| SCHEMBL12756945 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | claimed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | claimed |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2022-06-02 | — | — | US | disclosed |
| US-8541509-B2 | Polymers functionalized with protected oxime compounds | BRIDGESTONE CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | CHRM2 3/4885CHRM4 10/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.